Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

Sponsor: CivaTech Oncology

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT02843945

Patient View

This feasibility study assesses the safety and efficacy of the CivaSheet, a unidirectional brachytherapy device using Palladium-103, for treating borderline resectable pancreatic cancer. Eligible patients are adults undergoing specific surgeries without metastasis, having received prior chemoradiation. The device aims to deliver targeted radiation while sparing adjacent healthy tissue.

Patient Parameters

Program Overview

Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.

Description

This is a Feasibility study to determine the safety and efficacy of a new brachytherapy device that provides unidirectional radiation which utilizes active components (Palladium-103) of standard devices in a novel configuration.This pilot study may benefit pancreatic cancer patients by reducing the radiation dose to adjacent critical structures, while giving a therapeutic dose to diseased tissue, such as at a surgical margin. The appropriate dose and local control rate will be recorded the primary endpoint in order to provide an efficacy assessment.

Eligibility Criteria

Inclusion Criteria

  • • Subject signed inform consent

    • Age > 18 years
    • Not pregnant or breast feeding
    • Patient capable of undergoing anesthesia
    • Patient selected to undergo Whipple procedure or distal pancreatectomy
    • Patient does not have metastatic disease
    • Patients will have close margins
    • No prior radiation therapy to the region for separate cancer
    • Confirmed diagnosis of borderline resectable or locally advanced pancreatic adenocarcinoma
    • Patient Received neoadjuvant chemoradiation (4-10 weeks prior to surgery)
    • Chemotherapy was administered for 2-6 cycles with any combination of the following agents:
    • Gemcitabine + nb-paclitaxel
    • FOLFIRINOX
    • Neoadjuvant Chemoradiation was administered as IMRT or 3DCRT (up to 56 Gy), or SBRT (up to 36 Gy) with Pre-operative External beam dose (NCCN)
    • up to 56 Gy (1.8-2.0 Gy per fractions) with concurrent gemcitabine, capecitabine, or infusional 5-fluorouracil

Exclusion Criteria

  • Not surgical candidate
  • Any other invasive cancer in the past 5 years, except basal cell or squamous cell skin cancer
  • An IRE candidate (IRE is Percutaneous irreversible electroporation)
  • Recurrent or previously resected tumors
  • Documented History of Alcoholism and or drug abuse
  • Participant in other clinical trials

Get This Program In Your Inbox

You can sign up and apply your patients for this program.